Introduction
cancer, CINV, vomiting, diarrhea
SIDE EFFECT, GASTROINTESTINAL ULCERS, CANCER, DIFFICULTY SWALLOWING, CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
Chemotherapy-induced nausea and vomiting (CINV) is the most feared side effect reported for patients receiving chemotherapy [Although in most patients, acute CINV can be reasonably controlled with 5-HT3 receptor antagonists, delayed CINV remains a therapeutic challenge. The incidence of delayed CINV is often underestimated. Despite the use of antiemetic prevention, more than 50% of patients undergoing chemotherapy will experience this condition [With the increasing knowledge of substance P in vomiting, NK-1 receptor antagonists have been developed to treat delayed CINV. At present, NK-1 RAs can be obtained through oral and intravenous routes. It is convenient to take aprepitant orally, but failure to adhere to treatment may have a negative impact on the curative effect. Some cancer patients can not tolerate oral therapy, some patients may have difficulty swallowing, and the bioavailability of oral drugs may be reduced due to diarrhea or gastrointestinal ulcers [A phase III study for patients receiving 5-day cisplatin-based chemotherapy observed that it is safe and effective to prolong the duration of aprepitant in patients receiving 5-day cisplatin chemotherapy [